![Byong Kim](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Byong Kim
Director/Board Member at
LIPELLA PHARMACEUTICALS INC.
Net worth: - $ as of 2026-05-30
Profile
Byong Kim currently works at Lipella Pharmaceuticals, Inc., as Independent Director from 2022, CytoReason Ltd., as Independent Director, and Bridge Biotherapeutics, Inc., as Director & Executive Vice President from 2016.
Dr. Kim also formerly worked at Novartis Institutes for Biomedical Research, Inc., as Associate Director, Alkermes, Inc., as Principal, and Oxford Bioscience Partners, as Entrepreneur-in-Residence.
Dr. Kim received his Masters Business Admin degree from Carnegie Mellon University, doctorate degree from The University of Texas at Austin, and undergraduate degree from the University of California, Irvine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-03-25 | 0 ( -.--% ) | - $ | 2026-05-30 |
Byong Kim active positions
| Companies | Position | Start |
|---|---|---|
| LIPELLA PHARMACEUTICALS INC. | Director/Board Member | 2022-02-28 |
| PARATAXIS KOREA, INC. | Director/Board Member | 2015-12-31 |
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services Operates an artificial intelligence that develop computational model of the human body, accurate enough to start replacing animal and human trials in drug | Director/Board Member | - |
Former positions of Byong Kim
| Companies | Position | End |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | - |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Corporate Officer/Principal | - |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Private Equity Investor | - |
Training of Byong Kim
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
5
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Health Technology |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lipella Pharmaceuticals, Inc.
 Lipella Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes lipid-based therapies for common bladder syndromes | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Bridge Biotherapeutics, Inc.
 Bridge Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and biological products | Health Technology |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services Operates an artificial intelligence that develop computational model of the human body, accurate enough to start replacing animal and human trials in drug | Technology Services |
- Stock Market
- Insiders
- Byong Kim
